Fourman LT, Grinspoon SK. Approach to the Patient With Lipodystrophy. J Clin Endocrinol Metab. 2022 May 17. 107 (6):1714-1726. [QxMD MEDLINE Link].
Patni N, Alves C, von Schnurbein J, Wabitsch M, Tannin G, Rakheja D, et al. A Novel Syndrome of Generalized Lipodystrophy Associated With Pilocytic Astrocytoma. J Clin Endocrinol Metab. 2015 Oct. 100 (10):3603-6. [QxMD MEDLINE Link].
Lima JG, Nobrega LHC, Lima NN, Dos Santos MCF, Silva PHD, Baracho MFP, et al. Causes of death in patients with Berardinelli-Seip congenital generalized lipodystrophy. PLoS One. 2018. 13 (6):e0199052. [QxMD MEDLINE Link].
Bennett T, Allford M. Delayed emergence from anesthesia in a child with congenital generalized lipodystrophy (Berardinelli-Seip syndrome). Paediatr Anaesth. 2012 Mar. 22(3):299-300. [QxMD MEDLINE Link].
Rego AG, Mesquita ET, Faria CA, et al. [Cardiometabolic abnormalities in patients with berardinelli-Seip syndrome]. Arq Bras Cardiol. 2010 Jan. 94(1):109-18. [QxMD MEDLINE Link].
Al-Attar SA, Pollex RL, Robinson JF, Miskie BA, Walcarius R, Little CH, et al. Quantitative and qualitative differences in subcutaneous adipose tissue stores across lipodystrophy types shown by magnetic resonance imaging. BMC Med Imaging. 2007. 7:3. [QxMD MEDLINE Link].
Akinci B, Onay H, Demir T, et al. Natural History of Congenital Generalized Lipodystrophy: A Nationwide Study from Turkey. J Clin Endocrinol Metab. 2016 May 4. jc20161005. [QxMD MEDLINE Link].
Wang M, Cun Z, Peng J, et al. Type 2 congenital generalized lipodystrophy with a heterozygous missense NOTCH2 mutation. Eur J Clin Nutr. 2022 Jan 18. [QxMD MEDLINE Link].
Patni N, Xing C, Agarwal AK, Garg A. Juvenile-onset generalized lipodystrophy due to a novel heterozygous missense LMNA mutation affecting lamin C. Am J Med Genet A. 2017 Jul 7. [QxMD MEDLINE Link].
Jin J, Cao L, Zhao Z, et al. Novel BSCL2 gene mutation E189X in Chinese congenital generalized lipodystrophy child with early onset diabetes mellitus. Eur J Endocrinol. 2007 Dec. 157(6):783-7. [QxMD MEDLINE Link].
Knebel B, Kotzka J, Lehr S, Hartwig S, Avci H, Jacob S, et al. A mutation in the c-fos gene associated with congenital generalized lipodystrophy. Orphanet J Rare Dis. 2013 Aug 7. 8:119. [QxMD MEDLINE Link]. [Full Text].
Ceccarini G, Magno S, Pelosini C, Ferrari F, Sessa MR, Scabia G, et al. Congenital Generalized Lipoatrophy (Berardinelli-Seip Syndrome) Type 1: Description of Novel AGPAT2 Homozygous Variants Showing the Highly Heterogeneous Presentation of the Disease. Front Endocrinol (Lausanne). 2020. 11:39. [QxMD MEDLINE Link].
Araújo COD, Montenegro RM, Pedroso AP, Fernandes VO, Montenegro APDR, de Carvalho AB, et al. Altered acylated ghrelin response to food intake in congenital generalized lipodystrophy. PLoS One. 2021. 16 (1):e0244667. [QxMD MEDLINE Link].
Purizaca-Rosillo ND, Benites-Cóndor YE, Abarca Barriga H, Del Águila Villar C, Chávez Pastor M, Franco Palacios L, et al. High prevalence of congenital generalized lipodystrophy in Piura, Peru. Intractable Rare Dis Res. 2020 Feb. 9 (1):58-60. [QxMD MEDLINE Link].
Lima JG, Nobrega LH, de Lima NN, do Nascimento Santos MG, Baracho MF, Jeronimo SM. Clinical and laboratory data of a large series of patients with congenital generalized lipodystrophy. Diabetol Metab Syndr. 2016. 8:23. [QxMD MEDLINE Link].
Llamas-Velasco M, Daudén E, Martínez-Peñas G, García-Diez A. Late-Onset Acquired Generalized Lipodystrophy With Muscle Involvement. Actas Dermosifiliogr. 2011 Dec 19. [QxMD MEDLINE Link].
Scatteia A, Pagano C, Pascale C, Guarini P, Marotta G, Perrone-Filardi P, et al. Asymmetric hypertrophic cardiomyopathy in generalized lipodystrophy. Int J Cardiol. 2015 Oct 9. 202:724-725. [QxMD MEDLINE Link].
Faria CA, Moraes RS, Sobral-Filho DC, Rego AG, Baracho MF, Egito ES, et al. Autonomic modulation in patients with congenital generalized lipodystrophy (Berardinelli-Seip syndrome). Europace. 2009 Apr 17. [QxMD MEDLINE Link].
Solanki M, Patil SS, Baweja DK, Noorani H, Pk S. Talon cusps, macrodontia, and aberrant tooth morphology in Berardinelli-Seip syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008 Jan. 105(1):e41-7. [QxMD MEDLINE Link].
Haddad N, Vidal-Trecan T, Baroudjian B, Zagdanski AM, Arangalage D, Battistella M, et al. Acquired generalized lipodystrophy under immune checkpoint inhibition. Br J Dermatol. 2019 May 11. [QxMD MEDLINE Link].
Mork NJ, Rajka G, Halse J. Treatment of acanthosis nigricans with etretinate (Tigason) in a patient with Lawrence-Seip syndrome (generalized lipodystrophy). Acta Derm Venereol. 1986. 66(2):173-4. [QxMD MEDLINE Link].
Miehle K, Stumvoll M, Fasshauer M. [Lipodystrophy : Mechanisms, clinical presentation, therapy.]. Internist (Berl). 2011 Apr. 52(4):362-373. [QxMD MEDLINE Link].
Moran SA, Patten N, Young JR, Cochran E, Sebring N, Reynolds J, et al. Changes in body composition in patients with severe lipodystrophy after leptin replacement therapy. Metabolism. 2004 Apr. 53(4):513-9. [QxMD MEDLINE Link].
Gorden P, Gavrilova O. The clinical uses of leptin. Curr Opin Pharmacol. 2003 Dec. 3(6):655-9. [QxMD MEDLINE Link].
Javor ED, Cochran EK, Musso C, Young JR, Depaoli AM, Gorden P. Long-term efficacy of leptin replacement in patients with generalized lipodystrophy. Diabetes. 2005 Jul. 54(7):1994-2002. [QxMD MEDLINE Link].
Oral EA, Chan JL. Rationale for leptin-replacement therapy for severe lipodystrophy. Endocr Pract. 2010 Mar-Apr. 16(2):324-33. [QxMD MEDLINE Link].
Rodriguez AJ, Mastronardi CA, Paz-Filho GJ. New advances in the treatment of generalized lipodystrophy: role of metreleptin. Ther Clin Risk Manag. 2015. 11:1391-400. [QxMD MEDLINE Link].